1972-1980 Elementary school, Zagreb

1980-1984 High school (V gymnasium, Zagreb)

1984-1989 graduate school in molecular biology, Faculty of Science, University of Zagreb, B.Sc. in molecular biology

1989-1993 postgraduate study in molecular and cellular biology, Faculty of Science, University of Zagreb, M.Sc. in molecular and cellular biology

1993-1999 doctoral study, Faculty of Science, University of Zagreb, Ph.D. in molecular biology

2014 - 2018 "New Protein Networks for Novel Therapeutic Avenues in Human Melanoma - ProNetMel", research project by Croatian Science Foundation, principal investigator 

2007 –2013 "The role of p53/p73 protein network in soft tissue sarcoma“, Ministry of Science, Education and Sports, Republic of Croatia, principal investigator

2007-2008 “The role of p73 in cell cycle control”, French-Croatian bilateral project “Cogito”, principal investigator

2006.-2007."p53/p73 Network in chemoresistance. The relevance of dominant - negative p73 isoforms for chemosenstivity“; Austrian-Croatian bilateral project, principal investigator 

2007 "J.J. Strossmayer" Award by Croatian Academy of Sciences and Zagreb Fair for the best publishing venture:

University textbook “Methods in Molecular Biology”. Editors: Andreja Ambriović Ristov, Anamaria Brozović, Branka Bruvo Mađarić, Helena Ćetković, Maja Herak Bosnar, Dubravka Hranilović, Silva Katušić Hećimović, Nevenka Meštrović Radan, Snježana Mihaljević, Neda Slade,  Dušica Vujaklija; Zagreb, Ruđer Bošković Institute

2010 and 2012 Annual Director's Prize for scientific paper in the field of molecular medicine 

2003-2013: teaching Methodological courses in biology and medicine, RBI

2006-present: Doctoral study of Molecular Biosciences, RBI in collaboration with Universities in Osijek and Dubrovnik, teaching courses:
"Basic methods in molecular biology and medicine"   
"Methods in molecular biology and medicine –practical course"
"Tumor suppressor gene p53 and its relatives"
"Cell cycle control, genomic integrity maintenance and carcinogenesis"

2010-present: Doctoral study of Biology, Faculty of Science, University of Zagreb, teaching course "Genetics of cancer and biology of tumor cells"/from 2015 Biology of tumor cells

Zaika A.I., Slade N., Erster S., Sansome C., Joseph T.W., Pearl M., Chalas E., Moll U.M. DeltaNp73, a dominant negative inhibitor of wild type p53 and TA p73, is upregulated in human tumors. J Exp Med (2002) 196: 765-780.

Slade N., Zaika A.I., Erster S., Moll U.M. DeltaNp73 stabilizes TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ (2004) 11: 357-360.

Concin N., Becker K., Slade N., Erster S.,  Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., Moll U.M. Transdominant deltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 64: 2449–2460.

Moll U.M., Slade N. p63 and p73: Roles in Development and Tumor Formation. Mol Cancer Res (2004) 2: 371-386.

Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll M., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelić M., Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA (2007) 104: 12129-12134.

Slade N., Moll U.M., Brdar B., Zorić A., Jelaković B. p53 mutations as fingerprints for aristolochic acid – an environmental carcinogen in endemic (Balkan) nephropathy. MutatRes/Fund Mol M (2009) 663: 1-6.

Hofstetter G., Berger A., Fiegl H., Slade N., Zorić A., Holzer B., Schuster E., Mobus V.J., Reimer D., Daxenbichler G., Marth C., Zeimet A.G., Concin N.,Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene (2010) 29:1997-2004. 

Slade N., Horvat A. Targeting p73 - A Potential Approach in Cancer Treatment. Curr Pharm Des (2011) 17: 591-602.

Moriya M., Slade N., Brdar B., Medverec Z., Tomić K., Jelaković B., Wu L., Truong S., Fernandes A., Grollman AP. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer (2011) 129:1532-1536. 

Jelaković B., Karanović S., Vuković-Lela I., Miller  F., Edwards K., Nikolić J., Tomić K.,Slade N., Brdar B., Turesky R., Stipanćić Ž, Dittrich D., Grollman A.P., Dickman K.G. Aristolactam-DNA Adducts in the Renal Cortex: Biomarkers of Environmental Exposure to Aristolochic Acid. Kidney Int (2012) 81:559-567.

Zorić A, Horvat A,Slade N. Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis (2013) 34:522-529.

Laganović M, Bendix L, Rubelj I, Kirhmajer Vrkić M,Slade N, Vuković Lela I, Premužić V, Nilsson PM, Jelaković B. Reduced telomere length is not associated with early signs of vascular aging in young men born after intrauterine growth restriction: a paradox? J Hypertens (2014) 32:1613-1619.

Books and book chapters

Book chapters

• Moll, U. & Slade, N. (2005) The role of p53 and p73 genes in tumor formation. U: Hayat, M. (ur.) Handbook of Immunohistochemistry and in situ hibridization of human carcinomas. Vol 3: Molecular Genetics: Liver Carcinoma and Pancreatic Carcinoma. SAD, Academic Press, str. 103-117.

• Slade, N., Pavelić, J. & Pavelić, K. (2004) Gene therapy in oncology. U: Mršić-Krmpotić, Z. & Roth, A. (ur.) Internistička onkologija. Zagreb, Medicinska naklada, str. 80-113.

• Slade, N. & Moll, U. (2003) Mutational analysis of p53 in human tumors. Immunocytochemistry. U: Deb, S. & Palit Deb, S. (ur.) Methods in Molecular Biology: p53 Protocols. Totowa, New Jersey, USA, Humana Press, str. 231-243.

• Erster, S., Slade, N. & Moll, U. (2003) Mutational analysis of p53 in human tumors. Direct DNA sequencing and SSCP. U: Deb, S. & Palit Deb, S. (ur.) Methods in Molecular Biology: p53 Protocols. Totowa, New Jersey, USA, Humana Press, str. 219-230.

Journal articles

Scientific and review papers

• Radić, M., Šoštar, M., Weber, I., Ćetković, H., Slade, N. & Herak Bosnar, M. (2020) The Subcellular Localization and Oligomerization Preferences of NME1/NME2 upon Radiation-Induced DNA Damage. International journal of molecular sciences, 21 (7), 2363, 19 doi:10.3390/ijms21072363.

  doiwww.mdpi.comfulir.irb.hr

• Ozretić, P., Hanžić, N., Proust, B., Sabol, M., Trnski, D., Radić, M., Musani, V., Ciribilli, Y., Milas, I., Puljiz, Z., Bosnar Herak, M., Levanat, S. & Slade, N. (2019) Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Scientific Reports, 9 (1), 12470, 13 doi:10.1038/s41598-019-48882-y.

  doiwww.nature.comfulir.irb.hr

• Knezović Florijan, M., Ozretić, P., Bujak, M., Pezzè, L., Ciribilli, Y., Kaštelan, Ž., Slade, N. & Hudolin, T. (2019) The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic oncologic-seminars and original investigations, 37 (9), 578e, 10 doi:10.1016/j.urolonc.2019.03.007.

  doi

• Hanžić, N., Horvat, A., Bibić, J., Unfried, K., Jurkin, T., Dražić, G., Marijanović, I., Slade, N. & Gotić, M. (2018) Syntheses of gold nanoparticles and their impact on the cell cycle in breast cancer cells subjected to megavoltage X-ray irradiation. Materials science & engineering. C, Biomimetic materials, sensors and systems, 91, 486-495 doi:10.1016/j.msec.2018.05.066.

  doi

• Jazvinšćak Jembrek, M., Slade, N., Hof, P. & Šimić, G. (2018) The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. Progress in neurobiology, 168, 104-127 doi:10.1016/j.pneurobio.2018.05.001.

  doi

• Ravlić, S., Škrobot Vidaček, N., Nanić, L., Laganović, M., Slade, N., Jelaković, B. & Rubelj, I. (2017) Mechanisms of fetal epigenetics that determine telomere dynamics and health span in adulthood. Mechanisms of ageing and development, 175, 55-62 doi:10.1016/j.mad.2017.08.014.

  doi

• Slade, N., Zorić, A., Horvat, B., Vukšić, M., Kostović, I. & Poljak, L. (2015) Suppression of Smad-1 mRNA expression level by Smad-2 likely control dichotomy of NF-κB and Smads mediated activation. Immunobiology, 220 (1), 48-53 doi:10.1016/j.imbio.2014.09.003.

  doi

• Laganović, M., Bendix, L., Rubelj, I., Vrkić Kirhmajer, M., Slade, N., Vuković Lela, I., Premužić, V., Nilssonf, P. & Jelaković, B. (2014) Reduced telomere length is not associatedwith early signs of vascular aging in youngmen born after intrauterine growth restriction : a paradox?. Journal of hypertension, 32 (8), 1613-1620 doi:10.1097/HJH.0000000000000217.

  doi

• Zorić, A., Horvat, A. & Slade, N. (2013) Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis, 34 (3), 522-529 doi:10.1093/carcin/bgs370.

  doi

• Zorić, A., Horvat, A., Balija, M. & Slade, N. (2012) The Arg72Pro Polymorphism of TP53 in Croatian Population. Croatica chemica acta, 85 (2), 239-243 doi:10.5562/cca1866.

  doihrcak.srce.hr

• Jelaković, B., Karanović, S., Vuković-Lela, I., Miller, F., Edwards, K., Nikolić, J., Tomić, K., Slade, N., Brdar, B., Turesky, R., Stipančić, Ž., Dittrich, D., Grollman Arthur & Dickman, K. (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. KIDNEY INTERNATIONAL, 81 (6), 559-567 doi:10.1038/ki.2011.371.

  doi

• Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomić, K., Jelaković, B., Wu, L., Truong, S., Fernandes, A. & Grollman, A. (2011) TP53 Mutational signature for aristolochic acid : an environmental carcinogen. International journal of cancer, 129 (6), 1532-1536 doi:10.1002/ijc.26077.

  doi

• Slade, N. & Horvat, A. (2011) Targeting p73 - a potential approach in cancer treatment. Current pharmaceutical design, 17 (6), 591-602 doi:10.2174/138161211795222621.

  doi

• Slade, N., Zorić, A. & Horvat, A. (2010) The p53/p63/p73 family of proteins - the focus on isoforms and mutants in cancer. Periodicum biologorum, 112 (4), 425-432.

  hrcak.srce.hr

• Zorić, A., Horvat, A. & Slade, N. (2010) The p53 family of genes in development and tumor formation. Medicina Fluminensis, 46 (2), 135-143.

  hrcak.srce.hr

• Hofstetter, G., Berger, A., Fiegl, H., Slade, N., Zorić, A., Holzer, B., Schuster, E., Mobus, V., Reimer, D., Daxenbichler, G., Marth, C., Zeimet, A., Concin, N. & Zeillinger, R. (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53d is an independent prognostic marker in ovarian cancer. Oncogene, 29 (13), 1997-2004 doi:10.1038/onc.2009.482.

  doi

• Slade, N., Moll, U., Brdar, B., Zorić, A. & Jelaković, B. (2009) p53 mutations as fingerprints for aristolochic acid - an environmental carcinogen in endemic (Balkan) nephropathy. Mutation research, 663 (1-2), 1-6 doi:10.1016/j.mrfmmm.2009.01.005.

  doi

• Grollman, A., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., Jakovina, K., Brdar, B., Slade, N., Turesky, R., Goodenough, A., Rieger, R., Vukelić, M. & Jelaković, B. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proceedings of the National Academy of Sciences of the United States of America, 104 (29), 12129-12134 doi:10.1073/pnas.0701248104..

  doi

• Becker, K., Pancoska, P., Concin, N., Vanden Heuvel, K., Slade, N., Fischer, M., Chalas, E. & Moll, Ute, M. (2006) Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancer. International Journal of Oncology, 29 (4), 889-902.

• Moll, U. & Slade, N. (2004) p63 and p73: Roles in development and tumor formation. Mol Cancer Res (2004) 2: 371-386.. Molecular cancer research, 2, 371-386.

• Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A., Zeillinger, R., Marth, C. & Moll, U. (2004) Transdominant deltaTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo. Cancer research (Baltimore), 64 (7), 2449-2460.

• Slade, N. (2004) Two faces of p73, a member of p53 family. Periodicum biologorum, 106 (3), 223-231.

• Slade, N., Zaika, A., Erster, S. & Moll, U. (2004) DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death & Differentiation, 11 (3), 357-360.

• Dogan Koružnjak, J., Grdiša, M., Slade, N., Zamola, B., Pavelić, K. & Karminski-Zamola, G. (2003) novel derivatives of benzo((b)thieno(2, 3-c)quinolones: synthesis, photochemical synthesis, and antitumor evaluation. Journal of medicinal chemistry, 46 (21), 4516-4524.

• Džolić, Z., Cetina, M., Kovaček, D., Hergold-Brundić, A., Mrvoš-Sermek, D., Nagl, A., Slade, N., Pavelić, K., Balzarini, J., De Clercq, E., Zerbe, O., Folkers, G., Scapozza, L. & Mintas, M. (2003) Molecular structures and ab initio molecular orbital calculations of the optically active derivatives of 1-aminocyclopropane-1-carboxylic acid. Journal of molecular structure, 655 (2), 229-241.

• Džolić, Z., Krištafor, V., Cetina, M., Nagl, A., Hergold-Brundić, A., Mrvoš-Sermek, D., Burgemeister, T., Grdiša, M., Slade, N., Pavelić, K., Balzarini, J., De Clercq, E. & Mintas, M. (2003) Synthesis, structural studies and biological evaluation of some purine substituted 1- aminocyclopropane-1-carboxylic acids and 1-amino-1-hydroxymethylcyclopropanes. Nucleosides, nucleotides & nucleic acids, 22 (4), 373-389 doi:10.1081/NCN-120022029.

  doidoi.orgwww.tandfonline.com

• Dogan Koružnjak, J., Slade, N., Zamola, B., Pavelić, K. & Karminski-Zamola, G. (2002) Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno(3', 2':4, 5)thieno(2, 3-c)quinolones. Chemical and Pharmaceutical Bulletin, 50 (5), 656-660.

• Zaika, A., Slade, N., Erster, S., Sansome, C., Joseph, T., Pearl, M., Chalas, E. & Moll, U. (2002) Delta Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. Journal of Experimental Medicine, 196 (6), 765-780.

• Slade, N. (2001) Viral vectors in gene therapy. Periodicum biologorum, 103, 139-143.

• Slade, N., Galetić, I., Kapitanović, S. & Pavelić, J. (2001) The efficacy of retroviral herpes simplex virus thymidine kinase gene transfer and ganciclovir treatment on the inhibition of melanoma growth in viro and in vivo. Archives of Dermatological Research, 293, 484-490.

• Kapitanović, S., Radošević, S., Slade, N., Kapitanović, M., Anđelinović, Š., Ferenčić, Ž., Tavassoli, M., Spaventi, Š., Pavelić, K. & Spaventi, R. (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. Journal of Cancer Research and Clinical Oncology, 126 (4), 205-211.

• Slade, N., Štorga-Tomić, D., Birkmayer, G., Pavelić, K. & Pavelić, J. (1999) Effect of extracellular NADH on human tumor cell proliferation. Anticancer research, 19, 5355-5360.

• Pavelić, J., Slade, N., Galetić, I. & Pavelić, K. (1998) Gene therapy: principals and perspectives. Pharmaca, 36, 151-170.

• Slade, N., Kuzmić, I., Poljak, L., Krušlin, B., Pavelić, K. & Pavelić, J. (1995) Inverse relation between type IV collagenase and TGF-ß1 in human endometrial carcinoma. Tumordiagnostik & Therapie, 16 (6), 230-231.

• Slade, N., Pavelić, J., Krušlin, B. & Pavelić, K. (1995) Type IV collagenase in squamous cell and basal cell skin carcinomas. Archives of dermatological research, 287 (5), 512-514.

• Knežević, V., Spaventi, R., Poljak, L., Slade, N., Švajger, A. & Pavelić, K. (1994) p185neu is expressed in zolk sac during postimplantation development. Journal of anatomy, 185 (1), 181-187.

• Slade, N., Levanat, S., Spaventi, Š. & Pavelić, K. (1991) Collagenase derived from human fibrosarcoma is responsible for degradation of basement membranes. International journal of experimental pathology, 72 (6), 715-724.

  www.ncbi.nlm.nih.gov

• Pavelić, K., Despot Slade, N., Levanat, S. & Časl, T. (1990) Protective role of transforming growth factor beta (TGF b) in tumor-induced degradation of basement membranes. Journal of experimental pathology (Oxford), 371, 687-692.

Conference proceedings papers

Scientific conference proceedings papers

• Slade, N., Zorić, A., Horvat, B., Vukšić, M., Kostović, I. & Poljak, L. (2006) JAK-1/Smad signaling dependent genes expression associated with neurogenic to astrogliogenic transition point of brain development. U: Schwarzmeier, J. (ur.)The Proceedings of the 6th Joint Meeting of the International Cytokines Society (ICS), International Society of Interferon and Cytokine Research (ISICR) and the European Cytokine Society (ECS).

Patents

• Karminski-Zamola, G., Pavelić, K., Zamola, B., Dogan-Koružnjak, J., Grdiša, M. & Slade, N. (2000) Synthesis of new biologicaly active heterocycles from benzo-thieno-quinolone and thieno-thienyl-quinolone series, P2000118A.

• Tehnološki fakultet, Zagreb The synthesis of novel heterocyclic substances from the series of benzo-thieno-quinolones and thio-thienil-quinolones with biological activity, 00981104 (HR), 2000..

Theses

Doctoral dissertation

• Hanžić Nikolina (2018) 'Functional interplay between p53 and p53/p73, NME and GLI protein families in human melanoma', doktorska disertacija, Poslijediplomski interdisciplinarni sveučilišni studij Molekularne bioznanosti, Osijek.

  rektorat.unios.hr

• Slade, N. (1999) 'Tumor gene therapy by using the mechanism of cell suicide mediated by thymidine kinese gene', doktorska disertacija, Prirodoslovno-matematički, Zagreb.

Croatian Association for Cancer Research (branch of the European Association for Cancer Research), member of the Presidency

Croatian Society of Biochemistry and Molecular Biology

Croatian Biological Society

Committee of genomics and proteomics in oncology by Croatian Academy of Sciences and Arts 

Croatian Society of Human Genetic